CDKN2A and pachyonychia congenita: In addition, isolated KPIC cells that are orthotopically or intravenously injected into immunocompetent mice are tumorigenic and metastatic, revealing the synergistic effect of mutant P53 with KRAS and CDKN2. Thus, these cells are applicable for use in preclinical trials that examine PC with multiple genetic mutations.